The firm represented European-based private equity fund ArchiMed in its acquisition of Arkstone Medical Group, a biotechnology company providing clinical decision support powered by ML and AI, helping healthcare providers optimize antimicrobial use. The transaction will allow Arkstone expand its global footprint, deepen its R&D capabilities and bring its precision-guided technology to more clinicians around the world. Financial terms were not disclosed.
The Sheppard Mullin deal team that represented ArchiMed was led by partners Valerie Demont and Matt McCalip and associate Ines Briand. Invaluable assistance was provided by partners Niya Tang, Dmitry Chelnitsky, Daniel Yannuzzi, Sean Kirby, Reid Whitten and Carolyn Metnick, special counsel Malika Levarlet, and associates Theo Mayer, Michael Weisshar, Iman Naieem and Michael Sutton.
Read the press release here.